Logo-jnp
J Nephropathol. 2012;1(3): 123-125. doi: 10.5812/nephropathol.8106
PMID: 24475401        PMCID: PMC3886149

Editorial

Paraoxonase enzyme activity and dyslipidemia in chronic kidney disease patients

Mehrdad Solati 1 * , Hamid-Reza Mahboobi 2

Cited by CrossRef: 11

1- Baradaran A. Commentary on: effect of vitamin D on insulin resistance and anthropometric parameters in type 2 diabetes; a randomized double-blind clinical trial. DARU J Pharm Sci. 2013;21(1) [Crossref]
2- Nasri H. Reply: Oxytocin ameliorates cisplatin-induced nephrotoxicity in Wistar rats. Annals of Saudi Medicine. 2013;33(5):510 [Crossref]
3- Gautam G. Network Pharmacology-Based Validation of Traditional Therapeutic Claim of Momordica Charantiain Alleviating Diabetic Nephropathy. JCRP. 2022;1(1) [Crossref]
4- Nasri H. The protective effect of recombinant human erythropoietin against cisplatin-induced renal and hepatic dysfunctions in Wistar rats. Hum Exp Toxicol. 2014;33(10):1085 [Crossref]
5- Nematbakhsh M, Nasri H. Cisplatin nephrotoxicity may be sex related. Kidney International. 2013;83(6):1201 [Crossref]
6- Nasri H. C-Phycocyanin attenuates cisplatin-induced nephrotoxicity in mice. Renal Failure. 2013;35(7):1054 [Crossref]
7- G, Khan M, Basist P, Zahiruddin S, Ibrahim M, Parveen R, Krishnan A, Ahmad S. Nephroprotective potential of Boerhaavia diffusa and Tinospora cordifolia herbal combination against diclofenac induced nephrotoxicity. South African Journal of Botany. 2022;151:238 [Crossref]
8- Nasri H. Helicobacter pylori and Serum Magnesium Level in Hemodialysis Patients. Jundishapur J Microbiol. 2014;7(2) [Crossref]
9- Nasri R. Renoprotective effects of metformin. DARU J Pharm Sci. 2013;21(1) [Crossref]
10- Nasri H. Re Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes. Diabetes & Metabolism. 2013;39(4):375 [Crossref]
11- Mohammed C, Xie Y, Brewster P, Ghosh S, Dube P, Sarsour T, Kleinhenz A, Crawford E, Malhotra D, James R, Kalra P, Haller S, Kennedy D. Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease. JCM. 2019;8(7):1034 [Crossref]